A five-amino-acid peptide derived from salmon collagen reduced blood clot formation by 30% and prevented atherosclerotic plaque buildup in mice by targeting the same receptor as the drug clopidogrel.
30% thrombosis reductionachieved by a 5-amino acid salmon collagen peptide that targets the same P2Y12 receptor as the prescription drug clopidogrel
What the researchers found
The salmon collagen-derived peptide OGEFG (OG-5) inhibited platelet aggregation by antagonizing P2Y12 receptors, reduced tail thrombosis by 30% in a dose-dependent manner, and significantly reduced atherosclerotic plaque formation in ApoE-/- mice — with effects comparable to aspirin and no side effects. Molecular docking showed strong binding to P2Y12 receptors (-10.70 kcal/mol). OG-5 also inhibited inflammatory cytokine release and vascular smooth muscle cell migration in vitro.
Why it matters
Antiplatelet drugs like aspirin and clopidogrel (which targets P2Y12) are cornerstones of cardiovascular disease prevention but carry bleeding risks. A food-derived peptide that targets the same P2Y12 receptor with comparable anti-atherosclerotic effects and no observed side effects could represent a safer preventive approach for cardiovascular disease.
The numbers in context
30% reduction in tail thrombosis · -10.70 kcal/mol binding energy to P2Y12 · comparable effect to aspirin · no side effects in long-term administration
How the study worked
The 5-amino acid peptide OGEFG was tested for antiplatelet activity via aggregation assays (especially ADP-induced), P2Y12 receptor binding via molecular docking, and downstream signaling (PI3K-Akt and cAMP-VASP pathways). In vitro assays measured inflammatory cytokine release and smooth muscle cell migration. Long-term in vivo administration in ApoE-/- atherosclerosis mice compared plaque formation against aspirin control.
Who was studied
ApoE-/- atherosclerosis mouse model and in vitro cell assays (endothelial, macrophage, smooth muscle cells)
What this study cannot tell us
ApoE-/- mice are a standard atherosclerosis model but don't perfectly replicate human disease. Oral bioavailability and digestive stability of the peptide in humans are unknown. The aspirin comparison is qualitative — specific dosing equivalence was not established. Human clinical trials are needed to confirm safety and efficacy.
How to read the evidence
This is a preclinical study with strong mechanistic characterization (receptor binding, signaling pathways) and in vivo validation in an established atherosclerosis mouse model. The aspirin comparison strengthens the findings, but human data is absent.
When this study was published
Published in 2022, this study builds on growing research into marine-derived bioactive peptides for cardiovascular applications, a field that has expanded significantly in recent years.
The bigger picture
Food-derived bioactive peptides that target well-known drug receptors bridge the gap between nutrition and pharmacology. The P2Y12 receptor is one of the most important targets in cardiovascular medicine, and finding a natural peptide antagonist from a common food source (salmon collagen) opens possibilities for preventive nutritional approaches to heart disease — the world's leading cause of death.
Questions still open
- Would this peptide survive digestion intact enough to maintain its P2Y12 antagonist activity after oral consumption?
- Could salmon collagen hydrolysate supplements already on the market contain meaningful amounts of this peptide?
- Is there a bleeding risk with long-term use, given that it targets the same receptor as prescription antiplatelet drugs?
Common questions
What is the P2Y12 receptor and why is it important?
Could eating salmon provide enough of this peptide to have a health benefit?
Read the original research
A Collagen-Derived Oligopeptide from Salmo salar Collagen Hydrolysates Restrains Atherogenesis in ApoE-/- Mice via Targeting P2 Y12 Receptor.
Molecular nutrition & food research, 66(13), e2200166
Citation
Yang, Yijie; Liu, Hui; Cui, Liyuan; Liu, Yibo; Fu, Lulu; Li, Bo. (2022). A Collagen-Derived Oligopeptide from Salmo salar Collagen Hydrolysates Restrains Atherogenesis in ApoE-/- Mice via Targeting P2 Y12 Receptor.. Molecular nutrition & food research, 66(13), e2200166. https://doi.org/10.1002/mnfr.202200166